United Therapeutics Boosts Growth with Breakthrough Xenotransplant

United Therapeutics (UTHR) has surged 44.4% over six months, driven by the announcement of a successful first clinical xenotransplant for end-stage renal failure patients. This medical breakthrough, combined with double-digit revenue and profit growth, strengthens its outlook in regenerative therapies. Despite a slight revenue miss last quarter, expanding sales of its Tyvaso and Orenitram franchises support demand, bolstering investor confidence and maintaining an attractive valuation.